Publications by authors named "Shi-ming Lin"

Claim this Profile
P
Proton Beam Therapy Boosts Outcomes of Atezolizumab/Bevacizumab in Advanced Hepatocellular Carcinoma: A Propensity Score Analysis.
Yuan-Hung Kuo, Wei Teng, Po-Ting Lin, Yen-Hao Chen, Chung-Wei Su, Shi-Ming Lin, Chen-Chun Lin, Chun-Yen Lin

Liver Int· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted fetal NGS panel reveals genetic conditions in sonographically normal fetuses: Insights from a large cohort study.
Han-Ying Chen, Yi-Ting Wang, Jessica Kang, Yi-Yun Tai, Ti-Jia Yuan, Shin-Yu Lin, Shi-Ming Lin

PLoS One· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TKI plus ICI versus ICI alone in high tumor burden hepatocellular carcinoma: a retrospective cohort study.
Po-Ting Lin, Wei Teng, Wei-Ting Chen, Chung-Wei Su, Yi-Chung Hsieh, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin

J Cancer Res Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma.
Shuichiro Shiina, Ryosuke Tateishi, Joon Il Choi, So Yeon Kim, Zhiqiang Meng, Shi-Ming Lin

Liver Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma.
I-Cheng Lee, Hung-Wei Wang, Wei Teng, Tsung-Jung Lin, Chien-Hung Chen, Shi-Ming Lin

Clin Mol Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: Revisiting FOXP3 expression and its prognostic implications in hepatocellular carcinoma.
Chien-Hao Huang, Wei-Ting Ku, Tsung-Han Wu, Po-Ting Lin, Wei Teng, Chen-Chun Lin, Shi-Ming Lin, Yung-Chang Lin, Chun-Yen Lin

Hepatology· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moderate Immune-Related Liver Injury Is a Good Factor in Patients with Hepatoma Under Atezolizumab Plus Bevacizumab.
Tai-Chi Wu, Po-Ting Lin, Wei Teng, Eric Yi-Liang Shen, Chung-Wei Su, Chen-Chun Lin, Shi-Ming Lin, Chun-Yen Lin

Cancers (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatocellular carcinoma systemic treatment update: From early to advanced stage.
Wei Teng, Tai-Chi Wu, Shi-Ming Lin

Biomed J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study.
Yoon Jun Kim, Philippe Merle, Richard S Finn, Masatoshi Kudo, Heinz-Josef Klümpen, Shi-Ming Lin, Yih-Jyh Lin

Liver Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in HCC.
Chien-Hao Huang, Wei-Ting Ku, Jayashri Mahalingam, Cheng-Heng Wu, Tsung-Han Wu, Po-Ting Lin, Chen-Chun Lin, Shi-Ming Lin, Yung-Chang Lin, Chun-Yen Lin

Hepatology· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus Guideline of Ablation for Metastatic Liver Tumors by Taiwan Academy of Tumor Ablation.
Ming Shun Wu, Wei-Yu Kao, Ming-Feng Chiang, Po-Heng Chuang, Shih-Jer Hsu, Chen-Chun Lin, Shi-Ming Lin

Liver Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of Hepatic Arterial Infusion Chemotherapy with Tyrosine Kinase Inhibitor Provides Better Survival in Advanced Hepatocellular Carcinoma Patients.
Chung-Wei Liu, Po-Ting Lin, Wei Teng, Wei-Ting Chen, Chung-Wei Su, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin

J Hepatocell Carcinoma· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Bruno Sangro, Masatoshi Kudo, Joseph P Erinjeri, Shukui Qin, Zhenggang Ren, Shi-Ming Lin

Lancet· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.
Ying-Chun Shen, Tsung-Hao Liu, Alan Nicholas, Akihiko Soyama, Chang-Tsu Yuan, Po-Ting Lin, Shi-Ming Lin

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of Survival Impact from Hepatitis During Immunotherapy in 193 Patients with Advanced Hepatocellular Carcinoma - An Observational Study from Taiwan.
Chi-Han Lin, Yung-Chia Kuo, Hsuan-Chih Kuo, Ching-Ting Wang, Shi-Ming Lin

J Hepatocell Carcinoma· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression.
Tsung-Hao Liu, San-Chi Chen, Kun-Ming Rau, Li-Chun Lu, Po-Ting Lin, Shi-Ming Lin

Liver Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.
Wei Teng, Hung-Wei Wang, Shi-Ming Lin,

Liver Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis.
Yu-Chun Hsu, Po-Ting Lin, Wei Teng, Yi-Chung Hsieh, Wei-Ting Chen, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin

Cancers (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment.
Po-Ting Lin, Wei Teng, Wen-Juei Jeng, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin

J Formos Med Assoc· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma.
Chung-Wei Su, Wei Teng, Eric Yi-Liang Shen, Bing-Shen Huang, Po-Ting Lin, Chun-Yen Lin, Shi-Ming Lin, Chen-Chun Lin

Oncologist· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
:
: a pan-cancer biomarker and disulfidptosis regulator.
Xing Wang, Hong-Quan Zhu, Shi-Ming Lin, Bao-Ying Xia, Bo Xu

Transl Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor.
Po-Ting Lin, Yu-Chun Hsu, Yu-Ting Kao, Wei Teng, Yi-Chung Hsieh, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin

Am J Cancer Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A combination of locoregional treatment with systemic therapy after atezolizumab plus bevacizumab failure for unresectable hepatocellular carcinoma provides survival benefit.
Chung-Wei Su, Wei Teng, Po-Ting Lin, Tsung-Han Wu, Yu-Chun Hsu, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin

Am J Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors.
Hsiao-Mei Hsu, Hsin-I Tsai, Wei-Chen Lee, Chih-Chi Wang, Ming-Chin Yu, Shi-Ming Lin, Chun-Yen Lin

J Hepatocell Carcinoma· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adding nutritional status to the original BCLC stage improves mortality prediction for hepatocellular carcinoma patients in HBV-endemic regions.
Yan-Ting Lin, Po-Ting Lin, Chen-Chun Lin, Tsung-Han Wu, Li-Tong Liu, Chun-Yen Lin, Shi-Ming Lin

Am J Cancer Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis